ClinicalTrials.gg
CompletedNCT03224260Updated Jun 1, 2018

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

A Phase 1 interventional study of BMS-986177 and Matched Placebo in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-01.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
11th of 19
33 · median 42
Started
2017
with 3 others
Phase 1
13 of 19
none open now
Registered
16th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 11th largest by enrollment, is one of 4 that started in 2017, is one of 13 in phase 1, and was the 16th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be first-generation Japanese (born in Japan and not living outside of Japan for > 10 years; both parents must be ethnically Japanese)
  • 18.0 to 25.0 kg/m2, inclusive
  • Women must not be of nonchildbearing potential (cannot become pregnant)

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • History of allergy to BMS-986177 or other factor Xia inhibitors and/or formulation or history of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
  • History or evidence of abnormal bleeding or coagulation disorder

Other protocol defined inclusion and exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Treatment A

    Receive 50 mg BMS-986177 once daily or placebo

    Drug: BMS-986177 · Other: Matched Placebo

  • Experimental
    Treatment B

    Receive 200 mg BMS-986177 once daily or placebo

    Drug: BMS-986177 · Other: Matched Placebo

  • Experimental
    Treatment C

    Receive 500 mg BMS-986177 once daily or placebo

    Drug: BMS-986177 · Other: Matched Placebo

Interventions

  • Oral Suspension

  • OtherMatched Placebo

    Oral Suspension

06

What researchers measure

Primary outcomes

  1. Occurrence of Death

    Measured by investigator assessment

    Time frame: 30 days after last dose

  2. Incidence of Serious Adverse Events (SAEs)

    Measured by investigator assessment

    Time frame: 30 days after last dose

  3. Incidence of Adverse Events (AEs) Leading to Discontinuation of Study Therapy

    Measured by investigator assessment

    Time frame: 17 days

  4. Incidence of Adverse Events (AEs) Resulting in Clinically Significant Bleeding

    Measured by investigator assessment

    Time frame: 17 days

  5. Changes in Vital Signs (heart rate, systolic blood pressure, diastolic blood pressure, respiration rate, and temperature)

    Measured by investigator assessment

    Time frame: 17 days

  6. Change from baseline in electrocardiogram findings (ECGs)

    Measured by investigator assessment

    Time frame: 17 days

07

Study locations

1 site
  • West Coast Clinical Trials
    Anaheim, California 90630, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Nov 2017, 4 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2017
First posted
Jul 21, 2017
StartActual
Jun 28, 2017
Primary completionActual
Nov 7, 2017
CompletionActual
Nov 7, 2017
Last update
Jun 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03224260
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Jun 28, 2017
Primary completion
Nov 7, 2017
Completion
Nov 7, 2017
Last update
Jun 1, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion